WESTLAKE VILLAGE, Calif., Oct. 01, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD)
and (TASE:MNKD) will host a conference call on Monday, October 2, 2017 to discuss Company developments at 9:00 AM (Eastern
Time).
Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer,
Steven Binder.
To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the
participant passcode: 45747145. Those interested in listening to the conference call live via the Internet may do so by visiting
the Company's website at http://www.mannkindcorp.com under News & Events.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by
dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4574 7145#. A replay will also be available
on MannKind's website for 14 days.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the development and commercialization of inhaled
therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently
commercializing Afrezza® (insulin human) inhalation powder, the Company's first FDA approved product, in the United States, where
it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a
state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives
across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact:
Rose Alinaya
SVP, Investor Relations
818.661.5000
ir@mannkindcorp.com
